Delivery of therapeutic levels of heparin and low-molecular-weight heparin through a pulmonary route

AUTOR(ES)

Qi, Yiwei

FONTE

National Academy of Sciences

RESUMO

Although heparin and low-molecular-weight heparins (LMWH) have been widely used clinically as anticoagulants, their broader use has been limited by the lack of noninvasive delivery methods for this class of molecules. In this study, we demonstrate an efficient, rapid, and reproducible delivery system for heparin through the lungs that is not confined to particles of a certain geometric or aerodynamic diameter. Importantly, blood levels after intrapulmonary administration of either heparin or LMWH were comparable to that of s.c. administration but are characterized by a more rapid onset of action (t1/2 = 40 min vs. 2.5 h, respectively). Furthermore, we show in animal models, that inhaled heparin species efficiently inhibit diseases such as thrombosis and emphysema, and that the repetitive inhalation of formulated LMWH results in no observable toxicity from the delivery of reproducible systemic levels of heparin or LMWH.

Documentos Relacionados

• Pulmonary embolism in patients with COVID-19 and its treatment based on low-molecular-weight heparin
• LOW-MOLECULAR-WEIGHT RHEUMATOID FACTOR*
• Evidence for a low-molecular-weight collagen precursor.
• Low-molecular-weight xylanase from Trichoderma viride.
• Low-molecular-weight heparin and abciximab for thrombo-occlusive saphenous vein graft disease. Report of 2 cases.